Clinical Subgroups in Bilateral Meniere Disease.

dc.contributor.authorFrejo, Lidia
dc.contributor.authorSoto-Varela, Andres
dc.contributor.authorSantos-Perez, Sofía
dc.contributor.authorAran, Ismael
dc.contributor.authorBatuecas-Caletrio, Angel
dc.contributor.authorPerez-Guillen, Vanesa
dc.contributor.authorPerez-Garrigues, Herminio
dc.contributor.authorFraile, Jesus
dc.contributor.authorMartin-Sanz, Eduardo
dc.contributor.authorTapia, Maria C
dc.contributor.authorTrinidad, Gabriel
dc.contributor.authorGarcía-Arumi, Ana María
dc.contributor.authorGonzález-Aguado, Rocío
dc.contributor.authorEspinosa-Sanchez, Juan M
dc.contributor.authorMarques, Pedro
dc.contributor.authorPerez, Paz
dc.contributor.authorBenitez, Jesus
dc.contributor.authorLopez-Escamez, Jose A
dc.date.accessioned2025-01-07T17:29:29Z
dc.date.available2025-01-07T17:29:29Z
dc.date.issued2016-10-24
dc.description.abstractMeniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms, and tinnitus associated with several comorbidities, such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5 to 50%, and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD (BMD) to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of BMD and to develop new treatments. We have defined five clinical variants in BMD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to BMD.
dc.identifier.doi10.3389/fneur.2016.00182
dc.identifier.issn1664-2295
dc.identifier.pmcPMC5075646
dc.identifier.pmid27822199
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5075646/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fneur.2016.00182/pdf
dc.identifier.urihttps://hdl.handle.net/10668/28408
dc.journal.titleFrontiers in neurology
dc.journal.titleabbreviationFront Neurol
dc.language.isoen
dc.organizationCentro Pfizer-Andalucía de Genómica e Investigación Oncológica (GENYO)
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.organizationSAS - D.S.A.P. Jaén Norte
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.page.number182
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMeniere’s disease
dc.subjectautoimmune disorders
dc.subjectcluster analysis
dc.subjecthearing loss
dc.subjectinner ear
dc.subjectmigraine
dc.subjecttinnitus
dc.subjectvestibular disorders
dc.titleClinical Subgroups in Bilateral Meniere Disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number7

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC5075646.pdf
Size:
889.07 KB
Format:
Adobe Portable Document Format